Back to search results

Empagliflozin for Arterial Stiffness in Veterans with Obesity

This study is looking at how empagliflozin, a medication, affects the health of arteries (blood vessels) in Veterans who have obesity. You could be eligible if you are a Veteran between 30 and 60 years old, have obesity (BMI 30-45 kg/m2), and show signs of arterial stiffening. Participants will take either 10mg of empagliflozin daily or a placebo (an inactive pill) for 12 weeks. Researchers will measure your arterial stiffness at the beginning, and then at 4, 8, and 12 weeks to see if empagliflozin makes a difference. The current recruitment status is unclear.

Study design
This is a double-blinded, randomized, placebo-controlled study involving 50 Veterans. This means neither you nor the study team will know if you are receiving empagliflozin or the placebo.
What's involved
You would take either empagliflozin or a placebo daily for 12 weeks. Your arterial stiffness will be measured at the start, and again at weeks 4, 8, and 12.
Compensation
Not stated in the trial record.
Follow-up
Your arterial stiffness will be measured up to 12 weeks after starting the treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06745063

Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity

Recruiting
PHASE2Ages 30–60InterventionalTreatment
VA Office of Research and Development
~50 participants
Updated 2025-11-14 on ClinicalTrials.gov
What's tested:EmpagliflozinPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Carotid-femoral Pulse Wave Velocity (cfPWV)
Measured over baseline (t0), week 4, week 8, week 12

Conditions

Obesity
Vascular Health

Explore related trials

Obesity

Where it's being run

1 sites across 1 states
Missouri1

Study leadership

  • Jaume Padilla Parellada, PhD · PRINCIPAL_INVESTIGATOR · Harry S. Truman Memorial, Columbia, MO

Who to contact

Jaume Padilla Parellada, PhD
[email protected]
(573) 814-6552
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Body mass index (BMI) 30-45 kg/m2
30-60 years of age at randomization
Evidence of arterial stiffening (defined as Carotid femoral PWV\>age-predicted) at screening visit (PMID: 20530030)

Exclusion

Unable to provide consent
Diabetes mellitus
Uncontrolled hypertension (\>180/90mmHg) or systolic \<100mmHg at screening visit
Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease or stroke
Diagnosis of chronic kidney disease
Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)
Excessive alcohol consumption (\>14 drinks/week for men, \>7 drinks/week for women)
Use of GLP-1 analogs or SGLT2 inhibitors
Use of hormone replacement therapy
Use of pharmacological therapy for weight loss
Body weight changes \>10% within the past 6 months
History of hypersensitivity to nitrates
History of ketoacidosis
History of recurrent UTIs or mycotic genital infections
Use of anticoagulants
Change in anti-hypertensive medication regimen (if in use) during the last 90 days
Pregnancy

What this trial measures

  • Carotid-femoral Pulse Wave Velocity (cfPWV)baseline (t0), week 4, week 8, week 12

    cfPWV is the gold standard non-invasive index of arterial stiffness. Transit time between carotid and femoral pressure waves is calculated using the foot-to-foot method. cfPWV is calculated as distance traveled by the pulse wave (i.e., femoral location-sternal notch minus sternal notch-carotid location) divided by pulse transit time. All the measurements will be done by the same blinded technician. The goal is to assess changes from baseline when compared to weeks 4,8, and 12 time points.